Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Randomized, Crossover Assignment, Masking: Quadruple
Primary outcome measures:
ORR
The study showed that pexidartinib is effective in treating people with TGCT because it shrunk the size of their tumors and improved their symptoms and their ability to function. In general, people treated with pexidartinib had side effects that were mostly mild that went away after treatment with pexidartinib was stopped. The most common side effects were hair color changes and tiredness (fatigue). Pexidartinib was also associated with liver problems (or hepatotoxicity), which started within the first 2 months of treatment
Tap 2020 Future Oncology 16: 1875–1878
Pexidartinib is the first approved medication in the USA for people with tenosynovial giant cell tumor (TGCT) based on this trial
Tap 2020 Future Oncology 16: 1875–…